Metastatic Non-Small Cell Lung Cancer
Also known as: Metastatic Nonsmall Cell Lung Cancer / Metastatic NSCLC / Metastatic Non-Small Cell Lung Carcinoma / Metastatic Non-small Cell Lung Cancer (NSCLC) / Metastatic Non Small Cell Lung Cancer / Metastatic Non-Small-Cell Lung Cancer / Non-small cell lung cancer metastatic / Metastatic non-small cell lung cancer (disorder) / Lung cancer non-small cell stage IV / Non-small cell lung cancer stage IV
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB08916 | Afatinib | An antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy. |
| DB16695 | Amivantamab | An EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation. |
| DB11595 | Atezolizumab | A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. |
| DB12267 | Brigatinib | An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. |
| DB11791 | Capmatinib | A kinase inhibitor targeting c-Met receptor tyrosine kinase in the treatment of non-small cell lung cancer with MET exon 14 skipping. |
| DB14707 | Cemiplimab | A programmed death receptor-1 blocking antibody used to treat metastatic cutaneous squamous cell carcinoma. |
| DB08865 | Crizotinib | A receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive. |
| DB11963 | Dacomitinib | A medication used to treat non small cell lung cancer with EGFR exon 19 deletion of exon 21 L858R substitution. |
| DB11986 | Entrectinib | Entrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults. Entrectinib is also indicated in adults and children over 12 years old for the treatment... |
| DB00530 | Erlotinib | An EGFR tyrosine kinase inhibitor used to treat certain small cell lung cancers or advanced metastatic pancreatic cancers. |
| DB00317 | Gefitinib | A tyrosine kinase inhibitor used as first-line therapy to treat non-small cell lung carcinoma (NSCLC) that meets certain genetic mutation criteria. |
| DB12130 | Lorlatinib | An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. |
| DB16390 | Mobocertinib | An oral kinase inhibitor targeted against EGFR and used in the treatment of NSCLC with EGFR exon 20 insertion mutations. |
| DB09559 | Necitumumab | A monoclonal antibody used to treat metastatic squamous non-small cell lung cancer. |
| DB09035 | Nivolumab | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. |
| DB09330 | Osimertinib | A tyrosine kinase inhibitor used in the treatment of certain types of non-small cell lung carcinoma. |
| DB01229 | Paclitaxel | A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer. |
| DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
| DB15569 | Sotorasib | An experimental KRAS inhibitor being investigated for the treatment of KRAS G12C mutant non small cell lung cancer, colorectal cancer, and appendix cancer. |
| DB15133 | Tepotinib | An oral tyrosine kinase inhibitor targeted against MET for the treatment of metastatic non-small cell lung cancer in patients exhibiting MET exon 14 skipping mutations. |
| DB00361 | Vinorelbine | A vinca alkaloid used in the treatment of metastatic non-small cell lung carcinoma (NSLC) and in conjunction with other drugs in locally advanced NSCLC. |